Carlos Rodriguez-Galindo, MD
| Department | Genetics | |
| Hospital Title |
Director, Solid Tumor Program, Pediatric Oncology, Dana-Farber Cancer Institute Medical Director, Pediatric Oncology Clinical Trials, Pediatric Oncology, Dana-Farber Cancer Institute |
|
| Academic Title | Associate Professor, Department of Pediatrics, Harvard Medical School | |
| Phone | 617-632-4580 | |
| Fax | ||
| Carlos Rodriguez-Galindo | ||
| Location |
44 Binney Street Boston, MA 02115 |
Research Overview:
Dr. Rodriguez-Galindo’s clinical research has focused on the development of innovative therapies for pediatric solid tumors, in particular retinoblastoma, sarcomas, and rare cancers.
In the field of retinoblastoma, he leads a multidisciplinary team that integrates clinical and research initiatives focused on the development of a state of the art treatment center and advancement of science. In the RET5 protocol at St. Jude Children’s Research Hospital, he developed a comprehensive preclinical and clinical research program for the development of new agents and identification of molecular targets. In adrenocortical tumors, Dr. Rodriguez-Galindo has developed an international study through the Children’s Oncology Group (ARAR0332) that investigates biology and treatment of this malignancy. As part of those studies, unique patterns of gene expression that will help characterize those tumors with malignant behavior are being identified. He has also developed a national research study for pediatric nasopharyngeal carcinoma (ARAR0331) that incorporates new concepts in the treatment of this malignancy and explores the role of EBV in its pathogenesis.
Additional research initiatives in pediatric malignancies include his extensive work on the Ewing sarcoma, osteosarcoma and soft tissue sarcomas. Dr. Rodriguez-Galindo’s research in histiocytic disorders has centered in the use of nucleoside analogues in the treatment of Langerhans cell histiocytosis, which has led to the development of a phase II study of clofarabine in the treatment of children with refractory LCH. Dr. Rodriguez-Galindo is also the co-PI of the LCH-IV study of the Histiocyte Society.
His work on those fields has led to him assuming leadership roles in cooperative groups. Dr. Rodriguez-Galindo is the Chair of the Retinoblastoma and Rare Tumor Committee at the Children’s Oncology Group, and the Secretary of the Executive Board of the Histiocyte Society.
About Carlos Rodriguez-Galindo:
Dr. Rodriguez-Galindo received his Doctor in Medicine and Surgery at Autonomous University of Barcelona in Barcelona, Spain. He completed his residency in Pediatrics at Hospital Infantil "Vall d'Hebron" at Autonomous University of Barcelona in Barcelona, Spain. Dr. Rodriguez-Galindo completed his internship in Pediatrics at Hospital Infantil "Valle d'Hebron" in Barcelona, Spain and his fellowship in Pediatric Hematology/Oncology at St. Jude Children's Research Hospital in Memphis, TN.
